BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ponticelli C, Banfi G. Thrombotic microangiopathy after kidney transplantation. Transplant Int 2006;19:789-94. [DOI: 10.1111/j.1432-2277.2006.00354.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Matsuda D, Toshima T, Ikegami T, Harimoto N, Yamashita Y, Yoshizumi T, Soejima Y, Ikeda T, Shirabe K, Maehara Y. Thrombotic microangiopathy caused by severe graft dysfunction after living donor liver transplantation: report of a case. Clin J Gastroenterol 2014;7:159-63. [DOI: 10.1007/s12328-013-0446-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Kamar N, Rischmann P, Guilbeau-frugier C, Sallusto F, Khedis M, Delisle M, Noury D, Fort M, Rostaing L. Successful Retransplantation of a Kidney Allograft Affected by Thrombotic Microangiopathy Into a Second Transplant Recipient. American Journal of Kidney Diseases 2008;52:591-4. [DOI: 10.1053/j.ajkd.2008.03.037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
3 Mohsin N, Nooyi C, Jha A, Budruddin M, Kamble P, Khalil M, Pakkyarra A, Mohammed E, Ahmed H, Daar A. Retinal injury as an early manifestation of posttransplant thrombotic microangiopathy: recovery with plasma exchanges and conversion to sirolimus--case report and review of the literature. Transplant Proc 2007;39:1272-5. [PMID: 17524951 DOI: 10.1016/j.transproceed.2007.03.086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Devresse A, de Meyer M, Aydin S, Dahan K, Kanaan N. De Novo Atypical Haemolytic Uremic Syndrome after Kidney Transplantation. Case Rep Nephrol 2018;2018:1727986. [PMID: 29732228 DOI: 10.1155/2018/1727986] [Reference Citation Analysis]
5 Nava F, Cappelli G, Mori G, Granito M, Magnoni G, Botta C, Solazzo A, Fontana F, Baisi A, Bonucchi D. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation. Transplant Proc. 2014;46:2263-2268. [PMID: 25242766 DOI: 10.1016/j.transproceed.2014.07.062] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
6 Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, Fakhouri F, Provost F, Fridman WH, Thervet E. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant. 2008;8:1694-1701. [PMID: 18557729 DOI: 10.1111/j.1600-6143.2008.02297.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 97] [Article Influence: 8.2] [Reference Citation Analysis]
7 Dierickx D, Monbaliu D, De Rycke A, Wisanto E, Lerut E, Devos T, Meers S, Darius T, Ferdinande P, Pirenne J. Thrombotic microangiopathy following intestinal transplantation: a single center experience. Transplant Proc 2010;42:79-81. [PMID: 20172285 DOI: 10.1016/j.transproceed.2009.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
8 Leal R, Tsapepas D, Crew RJ, Dube GK, Ratner L, Batal I. Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation. Kidney Int Rep 2018;3:281-90. [PMID: 30276344 DOI: 10.1016/j.ekir.2017.10.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pasini E, Flati V, Paiardi S, Rizzoni D, Porteri E, Aquilani R, Assanelli D, Corsetti G, Speca S, Rezzani R, De Ciuceis C, Agabiti-Rosei E. Intracellular molecular effects of insulin resistance in patients with metabolic syndrome. Cardiovasc Diabetol 2010;9:46. [PMID: 20809949 DOI: 10.1186/1475-2840-9-46] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
10 Vilayur E, de Malmanche J, Trevillian P, Ferreira D. Metastatic lung adenocarcinoma- associated thrombotic microangiopathy in a renal transplant recipient. BMJ Case Rep 2018;11:e226707. [PMID: 30567242 DOI: 10.1136/bcr-2018-226707] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Bakhtar O, Thajudeen B, Braunhut BL, Yost SE, Bracamonte ER, Sussman AN, Kaplan B. A Case of Thrombotic Microangiopathy Associated With Antiphospholipid Antibody Syndrome Successfully Treated With Eculizumab. Transplantation 2014;98:e17-8. [DOI: 10.1097/tp.0000000000000267] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
12 Ashman N, Chapagain A, Dobbie H, Raftery MJ, Sheaff MT, Yaqoob MM. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant. 2009;9:424-427. [PMID: 19120084 DOI: 10.1111/j.1600-6143.2008.02482.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
13 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
14 Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, Pluthero FG, Kahr WH, Filler G, Hebert D, Harvey E, Licht C. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012;12:2546-53. [PMID: 22681773 DOI: 10.1111/j.1600-6143.2012.04124.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
15 Yılmaz VT, Koçak H, Avcı AB, Salim O, Ersoy FF, Süleymanlar G. Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient. Int Urol Nephrol 2011;43:581-4. [PMID: 20495869 DOI: 10.1007/s11255-010-9755-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-155. [PMID: 19845597 DOI: 10.1111/j.1600-6143.2009.02834.x] [Cited by in Crossref: 533] [Cited by in F6Publishing: 654] [Article Influence: 44.4] [Reference Citation Analysis]
17 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 20.6] [Reference Citation Analysis]
18 Chan MR, Thomas CP, Torrealba JR, Djamali A, Fernandez LA, Nishimura CJ, Smith RJ, Samaniego MD. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am J Kidney Dis. 2009;53:321-326. [PMID: 18805611 DOI: 10.1053/j.ajkd.2008.06.027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
19 Shochet L, Kanellis J, Simpson I, Ta J, Mulley W. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab. Nephrology (Carlton). 2017;22 Suppl 1:23-27. [PMID: 28176480 DOI: 10.1111/nep.12936] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
20 Kawaguchi K, Kawanishi K, Sato M, Itabashi M, Fujii A, Kanetsuna Y, Huchinoue S, Ohashi R, Koike J, Honda K, Nagashima Y, Nitta K. Atypical hemolytic uremic syndrome diagnosed four years after ABO-incompatible kidney transplantation. Nephrology (Carlton) 2015;20 Suppl 2:61-5. [PMID: 26031589 DOI: 10.1111/nep.12465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Takeda A, Ohtsuka Y, Horike K, Inaguma D, Goto N, Watarai Y, Uchida K, Morozumi K. A case of tacrolimus-associated thrombotic microangiopathy after ABO-blood-type-incompatible renal transplantation. Clin Transplant 2011;25 Suppl 23:15-8. [PMID: 21623908 DOI: 10.1111/j.1399-0012.2011.01453.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
22 Ellimoottil C, Brandt W, Bernardi K, Evans A, Mehta V, Picken MM, Phelan K, Heinrich L, Milner J, Wai PY, Asolati M, Kuo PC, Lu AD. Acute graft dysfunction after living-related renal transplant. Urology 2013;82:764-7. [PMID: 23947990 DOI: 10.1016/j.urology.2013.06.025] [Reference Citation Analysis]
23 Mutter WP, Stillman IE, Dahl NK. Thrombotic Microangiopathy and Renal Failure Exacerbated by ε-Aminocaproic Acid. American Journal of Kidney Diseases 2009;53:346-50. [DOI: 10.1053/j.ajkd.2008.07.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
24 Tanriover B, Lakhia R, Shen YM, Sandikci B, Saxena R, MacConmara M, Soyombo AA, Rajora N, Hardy MA. Characteristics and Outcomes of Renal Transplant Recipients with Hemolytic Uremic Syndrome in the United States. Transplant Direct 2015;1:e41. [PMID: 26949736 DOI: 10.1097/TXD.0000000000000555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Okumi M, Omoto K, Unagami K, Ishida H, Tanabe K. Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up. Int Urol Nephrol 2016;48:817-8. [PMID: 26865178 DOI: 10.1007/s11255-016-1234-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
26 Kadambi PV, Gamilla-Crudo AK, Almiani M, Josephson MA, Chon WJ. Differing tales of two patients after receiving a kidney transplant from a donor with disseminated intravascular coagulation. Case Rep Transplant 2014;2014:754256. [PMID: 25061532 DOI: 10.1155/2014/754256] [Reference Citation Analysis]
27 Devadoss CW, Vijaya V M, E M, Venkataramana S R, M S G. Tacrolimus associated localized thrombotic microangiopathy developing in early stage after renal transplantation. J Clin Diagn Res 2012;6:1786-8. [PMID: 23373055 DOI: 10.7860/JCDR/2012/4535.2614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Petr V, Hruba P, Kollar M, Krejci K, Safranek R, Stepankova S, Dedochova J, Machova J, Zieg J, Slatinska J, Pokorna E, Viklicky O. Rejection-associated Phenotype of De Novo Thrombotic Microangiopathy Represents a Risk for Premature Graft Loss. Transplant Direct 2021;7:e779. [PMID: 34712779 DOI: 10.1097/TXD.0000000000001239] [Reference Citation Analysis]
29 Koch M, Wiech T, Marget M, Peine S, Thude H, Achilles EG, Fischer L, Lehnhardt A, Thaiss F, Nashan B. De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation. Clin Transplant 2015;29:1021-8. [DOI: 10.1111/ctr.12624] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
30 Verbiest A, Pirenne J, Dierickx D. De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Reviews 2014;28:269-79. [DOI: 10.1016/j.blre.2014.09.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
31 Gungor O, Sen S, Kircelli F, Yilmaz M, Sarsik B, Ozkahya M, Hoscoskun C, Ok E, Toz H. Plasmapheresis Therapy in Renal Transplant Patients: Five-Year Experience. Transplantation Proceedings 2011;43:853-7. [DOI: 10.1016/j.transproceed.2011.03.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
32 Wilson CH, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation. 2011;92:e42-e43. [PMID: 21989273 DOI: 10.1097/tp.0b013e318230c0bd] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
33 De Ciuceis C, Flati V, Rossini C, Rufo A, Porteri E, Di Gregorio J, Petroboni B, La Boria E, Donini C, Pasini E, Agabiti Rosei E, Rizzoni D. Effect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: A pilot study. Blood Pressure 2014;23:330-8. [DOI: 10.3109/08037051.2014.901021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
34 Puttarajappa CM, Bernardo JF, Kellum JA. Renal Complications Following Lung Transplantation and Heart Transplantation. Crit Care Clin 2019;35:61-73. [PMID: 30447781 DOI: 10.1016/j.ccc.2018.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
35 Glassock RJ, Bargman JM, Palmer BF, Samaniego M, Fervenza FC. Nephrology Quiz and Questionnaire: 2009. CJASN 2010;5:1141-60. [DOI: 10.2215/cjn.00540110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Ponticelli C, Moroni G, Glassock RJ. De novo glomerular diseases after renal transplantation. Clin J Am Soc Nephrol. 2014;9:1479-1487. [PMID: 24700797 DOI: 10.2215/cjn.12571213] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
37 Satoskar AA, Pelletier R, Adams P, Nadasdy GM, Brodsky S, Pesavento T, Henry M, Nadasdy T. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant. 2010;10:1804-1811. [PMID: 20659088 DOI: 10.1111/j.1600-6143.2010.03178.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 56] [Article Influence: 6.0] [Reference Citation Analysis]
38 Malyszko J, Basak G, Batko K, Capasso G, Capasso A, Drozd-Sokolowska J, Krzanowska K, Kulicki P, Matuszkiewicz-Rowinska J, Soler MJ, Sprangers B, Malyszko J. Haematological disorders following kidney transplantation. Nephrol Dial Transplant 2020:gfaa219. [PMID: 33150431 DOI: 10.1093/ndt/gfaa219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Canet E, Zafrani L, Azoulay É. The Critically Ill Kidney Transplant Recipient: A Narrative Review. Chest 2016;149:1546-55. [PMID: 26836919 DOI: 10.1016/j.chest.2016.01.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
40 Portoles J, Huerta A, Arjona E, Gavela E, Agüera M, Jiménez C, Cavero T, Marrero D, Rodríguez de Córdoba S, Diekmann F; Matrix Investigators . Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J 2021;14:1173-80. [PMID: 33841863 DOI: 10.1093/ckj/sfaa096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35:25-40. [PMID: 31935318 DOI: 10.3904/kjim.2019.388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Java A, Edwards A, Rossi A, Pandey R, Gaut J, Delos Santos R, Miller B, Klein C, Brennan D. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. Transpl Int. 2015;28:1121-1125. [PMID: 25864519 DOI: 10.1111/tri.12582] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
43 Ivanyi B. A primer on recurrent and de novo glomerulonephritis in renal allografts. Nat Clin Pract Nephrol. 2008;4:446-457. [PMID: 18560395 DOI: 10.1038/ncpneph0854] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
44 Agustian PA, Bockmeyer CL, Modde F, Wittig J, Heinemann FM, Brundiers S, Dämmrich ME, Schwarz A, Birschmann I, Suwelack B. Glomerular mRNA expression of prothrombotic and antithrombotic factors in renal transplants with thrombotic microangiopathy. Transplantation. 2013;95:1242-1248. [PMID: 23635876 DOI: 10.1097/TP.0b013e318291a298] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
45 Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf. 2016;15:303-319. [PMID: 26667069 DOI: 10.1517/14740338.2016.1132698] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
46 Boothpur R, Brennan DC. Didactic lessons from the serum lactate dehydrogenase posttransplant: a clinical vignette. Am J Transplant 2008;8:862-5. [PMID: 18294352 DOI: 10.1111/j.1600-6143.2008.02151.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
47 Peeters P, Van Laecke S, Vanholder R. ACUTE KIDNEY INJURY IN SOLID ORGAN TRANSPLANT RECIPIENTS. Acta Clinica Belgica 2014;62:389-92. [DOI: 10.1179/acb.2007.087] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
48 de Nattes T, Lelandais L, Etienne I, Laurent C, Guerrot D, Bertrand D. Antithymocyte globulin-induced hemolytic anemia and thrombocytopenia after kidney transplantation. Immunotherapy 2018;10:737-42. [PMID: 30008258 DOI: 10.2217/imt-2017-0135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
49 Reindl-Schwaighofer R, Oberbauer R. Blood disorders after kidney transplantation. Transplant Rev (Orlando). 2014;28:63-75. [PMID: 24211181 DOI: 10.1016/j.trre.2013.10.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
50 Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report. Transplant Proc. 2011;43:2097-2101. [PMID: 21693335 DOI: 10.1016/j.transproceed.2011.02.064] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
51 Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 2010;56:1168-74. [PMID: 20843591 DOI: 10.1053/j.ajkd.2010.06.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
52 Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol 2008;23:1761-7. [PMID: 17906963 DOI: 10.1007/s00467-007-0616-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
53 Shindoh J, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Yamashiki N, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N. Thrombotic Microangiopathy After Living-Donor Liver Transplantation: TMA After LDLT. American Journal of Transplantation 2012;12:728-36. [DOI: 10.1111/j.1600-6143.2011.03841.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
54 Sreedharanunni S, Joshi K, Duggal R, Nada R, Minz M, Sakhuja V. An analysis of transplant glomerulopathy and thrombotic microangiopathy in kidney transplant biopsies. Transpl Int 2014;27:784-92. [PMID: 24684170 DOI: 10.1111/tri.12331] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
55 Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion. 2017;57:2775-2781. [PMID: 28836275 DOI: 10.1111/trf.14263] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
56 Caires RA, Marques ID, Repizo LP, Sato VA, Carmo LP, Machado DJ, de Paula FJ, Nahas WC, David-Neto E. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival. Transplant Proc 2012;44:2388-90. [PMID: 23026601 DOI: 10.1016/j.transproceed.2012.07.039] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
57 González-Roncero F, Suñer M, Bernal G, Cabello V, Toro M, Pereira P, Angel Gentil M. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012;44:2690-4. [PMID: 23146495 DOI: 10.1016/j.transproceed.2012.09.038] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
58 Wu K, Budde K, Schmidt D, Neumayer HH, Lehner L, Bamoulid J, Rudolph B. The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy. Clin Transplant. 2016;30:105-117. [PMID: 26448478 DOI: 10.1111/ctr.12645] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]